Gritstone Stock Moves Higher As It Advances COVID-19 Vaccine

Gritstone Oncology (NASDAQ: GRTS), a California based biotechnology company has seen its share price shoot higher premarket on Tuesday after it revealed it is advancing the development of a second-generation vaccine against coronavirus.

Gritstone’s shares are up 34.90% at $8.62.

Gritstone and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have entered into a clinical trial agreement to start clinical testing. A Phase 1 clinical trial is in development with the Bill & Melinda Gates Foundation supporting the preclinical evaluation.

X testing X

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

The company will have access to validated SARS-CoV-2 epitopes that have been identified through studies of hundreds of patients recovering from COVID-19, via a license agreement with the La Jolla Institute for Immunology (LJI).

“Since inception, Gritstone has developed two core assets – cutting-edge T cell epitope identification and potent vaccines shown to activate a strong and broad immune response in humans – and both of these have been deployed in our quest for a second generation SARS-CoV-2 vaccine,” said Andrew Allen, co-founder, president and CEO of Gritstone.